Life-Threatening Disease Articles & Analysis

Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to ...

By Orion Biotechnology Canada, Ltd.

AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir ...

By AlloVir

CDx Diagnostics, Inc. announced that the WATS3D view, published in Clinical Gastroenterology and Hepatology. WATS3D uses a unique wide-area sampling instrument, proprietary 3D imaging with AI analysis, and expert pathologists to reliably identify abnormal cells to help physicians prevent esophageal cancer. “The CPU is based on a thorough review of the existing clinical literature and ...

By CDx Diagnostics Inc.

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear ...

By 3DBio Therapeutics

Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...

By Infant Bacterial Therapeutics AB

SERB and BTG Specialty Pharmaceuticals are pleased to announce that Ben Watt has been named the group’s new Chief Financial Officer. Ben is an experienced CFO with a track record of building global finance teams and integrating business acquisitions. Ben most recently served as CFO of Crouzet, an independent manufacturer of electronic components used in heavily regulated industries. He ...

By BTG International Inc.

VISTA, Calif. — NOVEMBER 17, 2020 — Sommetrics, a private company developing products and services to improve sleep health, today announced its lead sleep apnea product, aerSleep II, has received FDA Breakthrough Device designation. This program allows for additional FDA feedback to sponsors during the pre-marketing phase but does not alter the basic requirements for market ...

By Sommetrics

TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to its lead drug candidate ILB® for the treatment of patients with amyotrophic lateral sclerosis (ALS) – a terminal, neurodegenerative disease where most patients die of respiratory muscle weakness in less than three to five years from symptom ...

By TIKOMED AB

IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...

By Infant Bacterial Therapeutics AB

VeriSIM Life (VeriSIM), the leading Artificial Intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced the acquisition of Molomics Biotech, a privately-held drug discovery company that leverages proprietary AI technology to design more efficacious and safer therapeutics to achieve higher successes in clinical trials. Founded in 2015 in ...

By VeriSIM Life

Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality ...

By Glycotest, Inc

The Offeror, Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis today announce that the conversion of Kiadis from a public limited liability company (naamloze vennootschap) into a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) shall be postponed until the Offeror has completed the statutory buy-out proceedings. In Section 6.13 of the Offer Memorandum the ...

By Kiadis Pharma NV

Glycotest, Inc. innovator Professor Anand Mehta, a leader in the development of glycoproteomic technologies for the discovery of novel cancer biomarkers, joins the Medical University of South Carolina (MUSC) and Hollings Cancer Center, Charleston, SC, as the new SmartState Endowed Chair of Proteomic Biomarkers, the company announced today (see MUSC). Mehta, whose work has resulted in 79 ...

By Glycotest, Inc

TVAX Biomedical today announced receipt of Fast Track Designation from the US Food and Drug Administration (FDA) for the use of its vaccineenhanced adoptive T cell therapy (VACT) for treatment of glioblastoma multiforme. “We are very pleased to receive Fast Track Designation by the FDA for glioblastoma multiforme (GBM),” stated Dr. Wayne Carter, Chief Executive Officer. Glioblastoma ...

By TVAX Biomedical, Inc.

Today, the U.S. Environmental Protection Agency (EPA) will recognize the City of Dallas and the Health and Wellness Alliance for Children for their collaboration to improve children’s health in the Dallas area. The groups are bringing together a variety of stakeholders to reduce environmental triggers for the 60,000 children in Dallas with asthma. Asthma is a serious, sometimes ...

By US EPA - Environmental Protection Agency

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure ...

By Regeneron Pharmaceuticals Inc.

Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant will provide funding for the continued ...

By Siolta Therapeutics

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...

By Infant Bacterial Therapeutics AB

Glycotest, Inc. announced today that a European patent has been granted and additional United States and Australian patents have been allowed. Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver ...

By Glycotest, Inc

Glycotest Inc., announced today that a Japanese patent has been granted that provides important protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and ...

By Glycotest, Inc